<DOC>
	<DOCNO>NCT01343459</DOCNO>
	<brief_summary>Title : HIOB - Hypofractionated Whole-Breast Irradiation precede Intraoperative Radiotherapy Electrons anticipate Boost ISIORT- 01 HIOB define hypofractionated WBRT ( 40,5 Gy 2,7 Gy per fraction ) precede Intraoperative Boost tumor bed ( 90 % reference dose 10 Gy , 11,1 Gy Dmax IOERT ) . Primary endpoint proof superiority new treatment regimen . The HIOB study concept suppose test hypothesis whether combined schedule superior ( iso-effective ) towards `` standard '' RT term local control cosmetic outcome . In vast majority publication , annual 5 year in-breast recurrence rate follow BCT show clear dependency patient age within follow boundary ( primary reference ) : Age &gt; 50 : Bartelink ( standard ) : 0,7 % ( annual ) 3,5 % ( 5y ) START B ( best ) : 0,4 % ( annual ) 2,0 % ( 5y ) Age 41-50 : Bartelink ( standard ) 1,2 % ( annual ) 6,0 % ( 5y ) Whelan ( best ) 0,72 % ( annual ) 3,6 % ( 5y ) Age ≥ 35-40 Bartelink ( standard ) 2 % ( annual ) 10 % ( 5y ) Whelan ( best ) 0,72 % ( annual ) 3,6 % ( 5y ) long three different age group , benchmarking perform best publish result follow ` Golden Standard ` RT , usually define conventionally fractionate WBRT 50 Gy ( 25 x2 ) plus external tumor bed boost 10-16 Gy electron ( 5-8x2Gy ) . Superiority define go low limit estimate 5 year local recurrence rate within respective age group Inferiority define cross respective upper limit . Secondary endpoint : Disease free survival Tertiary endpoint : toxicity assessment ( acute late ) include long term cosmetic evaluation Study design statistic : - Prospective multicenter single-armed - Sequential probability ratio test ( SPRT ) - Separate analysis within three different age group Estimated Accrual time : strongly dependent recruitment per year within respective age group . Due statistical estimation Szenario A B study close max . Time-period 10 year case A 6,4 year case B.. Principal investigator study coordinator : UC Radiotherapy Radio-Oncology UC Special Gynecology Breast Cancer Center Landeskrankenhaus Salzburg , Paracelsus University Clinics</brief_summary>
	<brief_title>Intra-Operative Electron Boost Hypofractionated Whole-Breast Irradiation During Breast-conserving Treatment ( BCT )</brief_title>
	<detailed_description>Study population : See Points 4.1 und 4.2 Inclusion/Exclusion criterion entire protocol Operation : - Lumpectomy / segmentectomy / tumorectomy sufficient safety margin ( see ) . Lymph node assessment must follow sentinel node concept . - Perioperative antibiotic prophylaxis mandatory - After IORT , radio-opaque clip fix tumor bed . Histology : R0-Resection mandatory Chemotherapy : neoadjuvant : allow adjuvant : allow . There limitation towards special chemotherapeutic scheme schedule . Radiotherapy : IOERT - IOERT perform mobile fix linac - Reference dose : 11 Gy specify maximum dose , minimum target volume dose 90 % encompass PTV ( i.e . 10 Gy ) . WBRT - must start within day 36- 56 postoperatively ( week 6 - 8 p.o . ) case adjuvant hormonal treatment ( tumor specific medication ) - In case adjuvant chemotherapy , time - gap IOERT WBRT 9 month allow . - Single reference dose per fraction : 2,7 Gy ( ICRU ) - Number fraction : 15 , Number fraction per week : 5 - Total WBRT dose : 40,5 Gy RT regional lymphatics : exclusion criterion Diagnostics Local recurrence : - yearly mammography , - optional breast sonography , MRI - LR histologically confirm Follow-up screen detection metastasis ( minimum requirement ) : - Chest X-Ray , optional - abdominal sonography , optional - lab test incl . tumor marker , optional Assessment acute toxicity WBRT accord CTC-toxicity Scoring-systems : Assessment late toxicity accord LENT-SOMA scoring-systems Assessment cosmetic outcome accord 5-point- Scoring System ( vanLimbergen ) start WBRT , include photo documentation standardize position</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Neoplasm Recurrence , Local</mesh_term>
	<criteria>Histological proven invasive breast carcinoma Age : ≥ 35 year Tumor stage T12 nodal status : N01 Freedom surgical margin : R0 ( invasive situ component ) , mean ink tumor ( invasive situ ) ( agoonline.de ) . Also multifocal disease within quadrant maximum distance &lt; 5 cm grade G1G3 Hormonal receptor Her2 status : limitation Informed undersign consent Insitu Carcinoma without invasive component Age &lt; 35 Tumor stage T3,4 Nodal status &gt; N1 irradiation regional lymphatics require R1 Reexcision IOERT Immediately secondary mastectomy ( due recurrence ) . Multicentricity accord international definition : &gt; 5 cm distance previous radiotherapy involve breast Karnofsky Index &lt; 70 % Mixed connective tissue disease include rheumatoid Polyarthritis , Thrombangitis obliterans Chronic preexistent lung disease ( Lung fibrosis , Pneumokoniosis , latetype Allergies like Farmer lung ; Asthma bronchiale , severe Emphysema , COPD III * ) Cardiac CoMorbidity : clinically positive coronary vessel disease , St.p . myocardial infarction , pacemaker and/or defibrillator ) Distant metastasis breast size ( PTV ) &gt; 2500 ml miss write consent observe pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hypofractionated Whole breast irradiation</keyword>
	<keyword>Hypofractionated Whole breast irradiation long term result</keyword>
	<keyword>Breast conserving therapy</keyword>
	<keyword>IORT electron breast cancer</keyword>
	<keyword>IOERT anticipate Boost</keyword>
	<keyword>IOERT hypofractionated whole breast irradiation</keyword>
</DOC>